Of the 60 cases of testicular infiltration previously reported (522 boys entered in UK ALL trials I-III between August 1970 and December 1974), 29 occurred during the first remission without other sign of leukaemic recurrence.' No treatment guidelines for testicular relapse had been laid down in the protocols of the trials, and as a result a variety of treatments was given. These treatments, their results, and related clinical data have been analysed retrospectively.
Results
Clinical presentation and diagnosis. The swelling of the testis was bilateral in 9 cases and unilateral in twenty. The firmness of the swelling was reported by most observers, but in only 2 patients was it painful. Twenty (69 %) patients had completed their course of [2] [3] years' chemotherapy, while 9 were still on treatment 10-36 months after diagnosis (Table) .
The diagnosis was established by orchidectomy in 12 cases, and by biopsy in 15 (5 needle aspirates and 10 wedge biopsies), but no histological confirmation was attempted in two.
In 10 cases tissue from only one testis was examined, but of 17 in which both were examined, 11 had bilateral infiltration, leaving 6 cases with a negative biopsy from the testis ofnormal size. Local treatment of the testis. Six patients were treated with unilateral orchidectomy alone, of whom 4 developed infiltration of the other testis after 6, 7 (confirmed at necropsy), 18, and 22 months.
Seventeen patients received radiotherapy in dosages from 900 to 2500 rad (Table) to the whole scrotum and inguinal regions, of whom 4 had subsequent testicular relapse 2, 5, 8, and 23 months later. In these 4, initial radiation dosages had been 900, 2000, 1000, and 2500 rad respectively. In 6 cases, unilateral orchidectomy was followed by standard field scrotal irradiation in dosages from 1400 to 2400 rad. None has subsequently relapsed in the opposite testis. There was a trend towards lower irradiation dosages for those relapsing locally than for those not relapsing, but it is not possible with groups containing so few to determine the significance of this difference, although it is important to note the single testicular relapse after 2500 rad.
Subsequent systemic treatment. The local control of the infiltrate was considered important, but the possibility that such deposits could re-seed the marrow or the central nervous system was not fully appreciated at that time. Therefore, systemic therapy after testicular relapse was variable in this series. One patient received no chemotherapy until relapse 3 months later. Twelve patients received 'reinduction' with vincristine and prednisolone for 3-4 weeks; in 5 of them this was followed by standard maintenance with 6-mercaptopurine and methotrexate and pulses of vincristine and prednisolone; three had multiple drug intensified maintenance and 4 had no further treatment. Eleven patients were restarted on their previous protocol without a specific 'reinduction' phase. The remaining 5 patients were 128
Isolated testicular relapse in acute lymphoblastic leukaemia ofchildhood 129 (5) Died (44) Died (22) Died (20) Died (19) Died (3) Died (14) Died (51) Died (6) Died (7) Died (7) Died (29) Died (8) Died (36) Died (7) Died (17) Died ( given more intensive therapy, including multiple drug combination 'induction' (prednisolone, vincristine, asparaginase, adriamycin/daunomycin, and cytosine arabinoside). If maintenance was given it was continued until the next relapse in 16 patients, for 3 months in one, 1 year in one, 18 months in one, and 2 years in six (Table) .
Next relapse. All but 5 patients have suffered a further relapse (Table) , either in the bone marrow (13 cases), central nervous system (3 cases), or testes (5 cases). There were two combined relapses, and one patient developed cervical, para-aortic, and mesenteric nodal enlargement at 3 months: that patient was the only one who had no further chemotherapy. Of the 4 receiving 'reinduction' chemotherapy only, all had early haematological relapse but this also occurred when therapy was intensive and more prolonged. Only 2 of the 29 patients received further prophylaxis to the central nervous system; one with intrathecal methotrexate and one with intrathecal methotrexate plus cytosine arabinoside. The last patient has a cerebral lesion, identified on computerised tomography scan, but without an excess of cells in the cerebrospinal fluid (probably not leukaemic in origin) and the other patient has had a further testicular relapse.
Three of the 5 cases still disease-free are from the group of 11 who started the same chemotherapy as before the relapse but without specific 'reinduction', and the other 2 are from the group of 7 who were treated with multiple drug combination therapy. All are now off treatment, having received 18-24 months' extra chemotherapy after testicular relapse. The disease-free survival after testicular relapse in the 29 cases is shown in Fig. 1. Survival. Fig. 2 
